Alkermes (ALKS:NASDAQ) Investor Relations Material

Overview

Dublin-based biopharmaceutical company Alkermes plc is making waves in the industry thanks to its groundbreaking pharmaceutical products catered towards unmet medical needs in various therapeutic areas. The company's marketed products include ARISTADA, a schizophrenia treatment, and VIVITROL, which helps prevent opioid and alcohol dependence. Its impressive repertoire also includes treatments geared towards bipolar disorder and multiple sclerosis. Alkermes is currently developing LYBALVI and nemvaleukin alfa, which have garnered significant attention in the medical community. The company has forged collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Founded in 1987, Alkermes plc is a promising figure in the biopharmaceutical industry.

Frequently Asked Questions

What is Alkermes's ticker?

Alkermes's ticker is ALKS

What exchange is Alkermes traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Alkermes's headquarters?

They are based in Dublin, Ireland

How many employees does Alkermes have?

There are 1001-5000 employees working at Alkermes

What is Alkermes's website?

It is alkermes.com

What type of sector is Alkermes?

Alkermes is in the Healthcare sector

What type of industry is Alkermes?

Alkermes is in the Biotechnology industry

Who are Alkermes's peers and competitors?

The following five companies are Alkermes's industry peers:

- Fate Therapeutics

- BeiGene, Ltd.

- Cassava Sciences, Inc.

- LogicBio Therapeutics, Inc.

- Exicure, Inc.